Lagger M; Najberg H; Miftaroski A; Widmer L; Di Renzo S; Iranmanesh P; Matter M; Tekdogan B; Perrodin S; Gloor B; Toso C; Frossard JL; Adamina M; Buhler L

Jan 1, 2026PloS one

2026PubMedDirectly related

Case report: Tirzepatide-responsive refractory diabetes mellitus in an adult female with prader-willi syndrome.

Li S; Yu J; Wei J; Liang M

Jan 1, 2026Medicine

2026PubMedDirectly related

Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA.

Tian Z; Willerding JM; Schmidt-Ott KM; Melk A; Schmidt BMW

Jan 1, 2026EClinicalMedicine

2026PubMedDirectly related

Lean Mass Reduction During Glucagon-like Peptide-1 Receptor Agonists-Induced Weight Loss: Rethinking Its Clinical Significance.

Moscucci F; Tocci G; Nardoianni G; Savoia C; Contino V; Leo G; Bocale R; Desideri G; Baratta F

Jan 1, 2026High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

2026PubMedDirectly related

Glucagon like peptide 1 receptor agonists in patients with inflammatory bowel disease: safety, clinical effectiveness and anti-inflammatory mechanisms.

Fernando S; Zhao J; Josloff K; Zubair N; Desai A; Shivashankar R; Kozuch PL; Choudhary C; Lichtenstein G; Sehgal P

Jan 1, 2026Frontiers in gastroenterology (Lausanne, Switzerland)

2026PubMedDirectly related

Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities.

Vahora S; Shah V; Patel B

Jan 1, 2026Pharmaceutical research

2026PubMedDirectly related

Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.

Ren L; Zhang Y; Fang F; Ma Y

Jan 1, 2026Diabetes, obesity & metabolism

2026PubMedDirectly related

Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.

Chen D; Ma B; Sun H; Zhang J; Gong L; Wang W; Liu Z; Zha H; Du S; Chen M; Sun W; Guo Q; Cao Y; Li Y

Jan 1, 2026BMJ medicine

2026PubMedDirectly related

Beyond Weight Loss: Disentangling the Direct Effects of Semaglutide vs Equivalent Calorie Restriction on Reproductive Systems of Male and Female Rats.

Sotzen MR; Byun S; Ibadin NO; Knappenberger MA; Bento MT; Asker M; Koshkin S; Diaz FJ; Skibicka KP

Jan 1, 2026Molecular metabolism

2026PubMedDirectly related

GLP1-RA Use and Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes.

Lee JJ; Brothers T; Kim LA; Ward KE; Yusuf H; Wen X

Jan 1, 2026Ophthalmology. Retina

2026PubMedDirectly related

Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.

Elgindi D; Petronic-Rosic V

Jan 1, 2026Clinics in dermatology

2026PubMedDirectly related

Patulous Eustachian tube dysfunction following rapid weight loss associated with semaglutide use: A case report.

Burmeister JR; Jawad M; Zazay I; Kobernick A

Jan 1, 2026SAGE open medical case reports

Page 13 of 21Showing 145-156 of total 251 results.

1...121314...21

GLP-1 receptor agonists for obesity treatment — Research Evidence and Topic... | Kritoma